林中天臺灣大學:獸醫學研究所林念庭Lin, Nien-TingNien-TingLin2010-05-042018-07-092010-05-042018-07-092008U0001-0807200811580000http://ntur.lib.ntu.edu.tw//handle/246246/178888正常眼角膜構造為透明無血管生長，當發生感染、炎症、乾眼症等角膜疾病時，眼角膜常會出現許多新生血管生成，過多的新生血管會導致炎症反應加劇，且導致眼角膜的透明度降低或喪失。血管內皮生長因子(vascular endothelium growth factor, VEGF) 在其中扮演了非常重要的角色，我們實驗以抗血管內皮生長因子(Anti-VEGF)藥物來拮抗血管內皮生長因子的作用進而阻斷角膜新生血管作用。實驗使用紐西蘭白兔進行體內試驗，我們以三種模式來建立角膜新生血管：角膜微晶格模式、角膜輪狀部幹細胞缺損模式及角膜化學灼傷模式。抗血管內皮生長因子藥物選擇Bevacizumab (AvastinThe cornea is an avascular transparent structure normally. Corneal neovascularization may be initiated following infection, trauma, and inflammation, leading to decreased corneal transparency. Additionally, corneal neovascularization is a risk factor for graft rejection after allograft corneal transplantation. Vascular endothelium growth factor (VEGF) is known to have an important role in angiogenesis in the body. The anti-VEGF drugs have been proved to inhibit VEGF in previous reports on cancers and retina. In this study, we investigated the effects of anti-VEGF drug on corneal neovascularization in a rabbit model. Three models of corneal neovascularization in rabbits were used in this study, namely corneal micropocket, limbal stem cell insufficiency, and chemical burn. The anti-VEGF drug, bevacizumab (Avastin), was injected subconjunctivally for treating corneal neovascularization in these rabbit models. The maximal length and area of corneal neovascularization were measured and recorded. Histology analysis and immunochemical staining of the rabbit cornea were performed. Bevacizumab revealed inhibitory effect of corneal neovascularization in all of the three models. The treatment group showed lesser corneal neovascularization, inflammatory cells infiltration, and vascular endothelium cells by histology. Immunochemical stain revealed the expressions of the vascular endothelial cells and bevacizuzmab in cornea. In conclusion, subconjunctival injection of anti-VEGF drug, bevacizumab, can effectively suppress corneal neovascularization with no significant side effects based on this study. The dosage, administration routes, and efficacy in corneal diseases and allografts remains to investigate in the future.目錄試委員會審定書 i謝 ii文摘要 iii文摘要 iv一章 緒論 1一節 角膜新生血管 1二節 角膜新生血管之治療 2三節 研究目的 2二章 文獻探討 3一節 角膜新生血管之生理機制 3二節 角膜新生血管之治療 6三節 抗血管內皮生長因子藥物 7三章 實驗材料與方法 10一節 實驗材料 10二節 實驗方法 10、 角膜微晶格模式 10、 角膜輪狀部幹細胞缺損模式 11、 角膜化學灼傷模式 12、 組織病理學 12、 統計分析方法 13四章 實驗結果 14一節 角膜微晶格模式 14二節 角膜輪狀部幹細胞缺損模式 14三節 角膜化學灼傷模式 15四節 組織病理學 15五章 討論 17一節 血管內皮生長因子在角膜新生血管作用參與機制及治療成果 17二節 纖維母細胞生長因子在角膜新生血管作用參與機制及治療成果 18三節 角膜新生血管模式比較 20四節 Bevacizumab控制角膜新生血管的效果及在角膜的分布狀況 22五節 角膜新生血管在獸醫的發展 25六節 Bevacizumab的副作用研究 26六章 結論 28考文獻 29目錄 37目錄 47application/pdf2063242 bytesapplication/pdfen-US角膜新生血管血管內皮生長因子癌思停corneaneovascularizationvascular endothelium growth factor (VEGF)bevacizumab[SDGs]SDG3thesishttp://ntur.lib.ntu.edu.tw/bitstream/246246/178888/1/ntu-97-R94629025-1.pdf